Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series.
Burosumab
FGF23
Hypophosphatemia
Phosphate
TIO
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
09
01
2022
accepted:
08
03
2022
pubmed:
7
4
2022
medline:
3
6
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
Tumor induced osteomalacia (TIO) is a rare disease of mineral metabolism, whose clinical picture is dominated by hypophosphatemia usually due to an excess of circulating FGF23 produced by small mesenchymal tumors. Data on the real prevalence of the disease are lacking, with the knowledge of the disease mainly relying on case reports and small case series. No estimate is available on the prevalence of uncured TIO. National multi-center, cross-sectional and retrospective study on persistent or recurrent cases of TIO followed in referral centers for bone diseases; systematic review of the published persistent and recurrent cases of TIO. Data from patients consecutively evaluated in referral Italian centers for bone diseases were collected; a PubMed search on persistent, recurrent and unoperable cases of TIO was carried out. Sixteen patients (mean age at diagnosis 52.5 ± 10.6 years) with persistent (n = 6, 37,5%), recurrent (n = 7, 43.7%) or not operable (n = 3, 18.8%) TIO were described. Delay in diagnosis (2.5 ± 1.3 years) was demonstrated. All patients experienced fragility fractures or pseudofractures and disabling bone and muscle pain. BMD was significantly reduced (mean T-score -2.7 ± 1.7 and -2.7 ± 0.9 at lumbar spine and femoral neck, respectively). Fourteen patients were maintained under therapy with phosphate salts and calcitriol, while in 2 patients therapy with burosumab, an anti-FGF23 antibody, was commenced. A significant number of patients with TIO remain either undiagnosed for tumor localization or tumor recur or persist after surgery. These patients with active disease represent possible candidates for burosumab treatment.
Identifiants
pubmed: 35381903
doi: 10.1007/s12020-022-03039-2
pii: 10.1007/s12020-022-03039-2
pmc: PMC9156492
doi:
Substances chimiques
Fibroblast Growth Factors
62031-54-3
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
709-721Informations de copyright
© 2022. The Author(s).
Références
A.L. Folpe, J.C. Fanburg-Smith, S.D. Billings, M. Bisceglia, F. Bertoni, J.Y. Cho et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: An analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 28(1), 1–30 (2004). https://doi.org/10.1097/00000478-200401000-00001
doi: 10.1097/00000478-200401000-00001
pubmed: 14707860
J.M. Boland, P.J. Tebben, A.L. Folpe, Phosphaturic mesenchymal tumors: What an endocrinologist should know. J Endocrinol Invest. 41(10), 1173–84 (2018). https://doi.org/10.1007/s40618-018-0849-5
doi: 10.1007/s40618-018-0849-5
pubmed: 29446010
P. Florenzano, I.R. Hartley, M. Jimenez, K. Roszko, R.I. Gafni, M.T. Collins, Tumor-induced Osteomalacia. Calcif Tissue Int. 108(1), 128–42 (2021). https://doi.org/10.1007/s00223-020-00691-6
doi: 10.1007/s00223-020-00691-6
pubmed: 32504138
I. Endo, S. Fukumoto, K. Ozono, N. Namba, D. Inoue, R. Okazaki et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J. 62(9), 811–6 (2015). https://doi.org/10.1507/endocrj.EJ15-0275
doi: 10.1507/endocrj.EJ15-0275
pubmed: 26135520
R.A. McCANCE, Osteomalacia with Looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 16(1), 33–46 (1947)
pubmed: 20296654
A. Prader, R. Illig, E. Uehlinger, G. Stalder, [Rickets following bone tumor]. Helvetica Paediatrica Acta. 14, 554–65 (1959)
pubmed: 14434619
M. Sundaram M, E.F. McCarthy, Oncogenic osteomalacia. Skelet Radio. 29(3), 117–24 (2000). https://doi.org/10.1007/s002560050581
doi: 10.1007/s002560050581
P. Florenzano, R.I. Gafni, M.T. Collins, Tumor-induced osteomalacia. Bone Rep. 7, 90–7 (2017). https://doi.org/10.1016/j.bonr.2017.09.002
doi: 10.1016/j.bonr.2017.09.002
pubmed: 29021995
pmcid: 5633085
S. Fukumoto, Phosphate metabolism and vitamin D. BoneKEy Rep. 3, 497 (2014). https://doi.org/10.1038/bonekey.2013.231
doi: 10.1038/bonekey.2013.231
pubmed: 24605214
pmcid: 3944128
S. Minisola, M. Peacock, S. Fukumoto, C. Cipriani, J. Pepe, S.H. Tella et al. Tumour-induced osteomalacia. Nat Rev Di Prim. 3, 17044 (2017). https://doi.org/10.1038/nrdp.2017.44
doi: 10.1038/nrdp.2017.44
G. Marcucci, L. Masi, S. Ferrari, D. Haffner, M.K. Javaid, P. Kamenický et al. Phosphate wasting disorders in adults. Osteoporos Int. 29(11), 2369–87 (2018). https://doi.org/10.1007/s00198-018-4618-2
doi: 10.1007/s00198-018-4618-2
pubmed: 30014155
P.J. Marie, F.H. Glorieux, Histomorphometric study of bone remodeling in hypophosphatemic vitamin D-resistant rickets. Metab Bone Dis Relat Res. 3(1), 31–8 (1981). https://doi.org/10.1016/s0221-8747(81)80020-3
doi: 10.1016/s0221-8747(81)80020-3
pubmed: 6267414
G. González, R. Baudrand, M.F. Sepúlveda, N. Vucetich, F.J. Guarda, P. Villanueva et al. Tumor-induced osteomalacia: Experience from a South American academic center. Osteoporos Int. 28(7), 2187–93 (2017). https://doi.org/10.1007/s00198-017-4007-2
doi: 10.1007/s00198-017-4007-2
pubmed: 28341900
W.H. Chong, P. Andreopoulou, C.C. Chen, J. Reynolds, L. Guthrie, M. Kelly et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res. 28(6), 1386–98 (2013). https://doi.org/10.1002/jbmr.1881
doi: 10.1002/jbmr.1881
pubmed: 23362135
A.H. Hautmann, M.G. Hautmann, O. Kölbl, W. Herr, W.M. Fleck, Tumor-induced osteomalacia: An up-to-date review. Curr Rheumatol Rep. 17(6), 512 (2015). https://doi.org/10.1007/s11926-015-0512-5
doi: 10.1007/s11926-015-0512-5
pubmed: 25900190
W.H. Chong, A.A. Molinolo, C.C. Chen, M.T. Collins, Tumor-induced osteomalacia. Endocr Relat Cancer 18(3), R53–R77 (2011). https://doi.org/10.1530/ERC-11-0006
doi: 10.1530/ERC-11-0006
pubmed: 21490240
pmcid: 3433741
Q.L. Huang, D.S. Feig, M.E. Blackstein, Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. J Endocrinol Invest. 23(4), 263–7 (2000). https://doi.org/10.1007/BF03343720
doi: 10.1007/BF03343720
pubmed: 10853715
D. Ovejero, D. El-Maouche, B.A. Brillante, A. Khosravi, R.I. Gafni, M.T. Collins, Octreotide is ineffective in treating tumor-induced osteomalacia: Results of a short-term therapy. J Bone Miner Res. 32(8), 1667–71 (2017). https://doi.org/10.1002/jbmr.3162
doi: 10.1002/jbmr.3162
pubmed: 28459498
E.A. Imel, F.H. Glorieux, M.P. Whyte, C.F. Munns, L.M. Ward, O. Nilsson et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 393(10189), 2416–27 (2019). https://doi.org/10.1016/S0140-6736(19)30654-3
doi: 10.1016/S0140-6736(19)30654-3
pubmed: 31104833
pmcid: 7179969
K.L. Insogna, K. Briot, E.A. Imel, P. Kamenický, M.D. Ruppe, A.A. Portale et al. AXLES 1 investigators. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an Anti-FGF23 antibody, in adults with X-Linked hypophosphatemia: Week 24 primary analysis. J Bone Miner Res. 33(8), 1383–93 (2018). https://doi.org/10.1002/jbmr.3475
doi: 10.1002/jbmr.3475
pubmed: 29947083
A.A. Portale, T.O. Carpenter, M.L. Brandi, K. Briot, H.I. Cheong, M. Cohen-Solal et al. Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: Results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int. 105(5), 271–84 (2019). https://doi.org/10.1007/s00223-019-00568-3
doi: 10.1007/s00223-019-00568-3
pubmed: 31165191
E.A. Imel, A. Biggin, A. Schindeler, C.F. Munns, FGF23, hypophosphatemia, and emerging treatments. J Bone Miner Res. 3(8), e10190 (2019). https://doi.org/10.1002/jbm4.10190
doi: 10.1002/jbm4.10190
Y. Imanishi, N. Ito, Y. Rhee, Y. Takeuchi, C.S. Shin, Y. Takahashi et al. Fukumoto. interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia. J Bone Miner Res. 36(2), 262–70 (2021). https://doi.org/10.1002/jbmr.4184
doi: 10.1002/jbmr.4184
pubmed: 32967046
S.M. Jan de Beur, P.D. Miller, T.J. Weber, M. Peacock, K. Insogna, R. Kumar et al. Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res. 36(4), 627–35 (2021). https://doi.org/10.1002/jbmr.4233
doi: 10.1002/jbmr.4233
R. Shah, A.R. Lila, R.S. Jadhav, V. Patil, A. Mahajan, S. Sonawane et al. Tumor induced osteomalacia in head and neck region: Single center experience and systematic review. Endocr Connect. 8(10), 1330–53 (2019). https://doi.org/10.1530/EC-19-0341
doi: 10.1530/EC-19-0341
pubmed: 31505461
pmcid: 6790902
R. Pal, S.K. Bhadada, A. Singhare, A. Bhansali, S. Kamalanathan, M. Chadha et al. Tumor-induced osteomalacia: experience from three tertiary care centers in India. Endocr. Connect. 8(3), 266–76 (2019). https://doi.org/10.1530/EC-18-0552
doi: 10.1530/EC-18-0552
pubmed: 30726771
pmcid: 6410764
Q.-Y. Zuo, H. Wang, W. Li, X.-H. Niu, Y.-H. Huang, J. Chen et al. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients. BMC Musculoskelet Disord. 18(1), 403 (2017). https://doi.org/10.1186/s12891-017-1756-1
doi: 10.1186/s12891-017-1756-1
pubmed: 28934935
pmcid: 5609032
H. Kobayashi, T. Akiyama, T. Okuma, Y. Shinoda, H. Oka, N. Ito et al. Three-dimensional fluoroscopic navigation-assisted surgery for tumors in patients with tumor-induced osteomalacia in the bones. Comput Assist Surg. 22(1), 14–9 (2017). https://doi.org/10.1080/24699322.2017.1282044
doi: 10.1080/24699322.2017.1282044
H. Wang, D. Zhong, Y. Liu, Y. Jiang, G. Qiu, X. Weng et al. Surgical treatments of tumor-induced osteomalacia lesions in long bones: Seventeen cases with more than one year of follow-up. J Bone Jt Surg Am. 97(13), 1084–94 (2015). https://doi.org/10.2106/JBJS.N.01299
doi: 10.2106/JBJS.N.01299
C.K. Ledford, N.A. Zelenski, D.M. Cardona, B.E. Brigman, W.C. Eward, The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed? Clin Orthop Relat Res. 471(11), 3618–25 (2013). https://doi.org/10.1007/s11999-013-3178-1
doi: 10.1007/s11999-013-3178-1
pubmed: 23868423
pmcid: 3792251
Y. Jiang, W. Xia, X. Xing, B.C. Silva, M. Li, O. Wang et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J Bone Miner Res. 27(9), 1967–75 (2012). https://doi.org/10.1002/jbmr.1642
doi: 10.1002/jbmr.1642
pubmed: 22532501
N. Naswa, P. Sharma, R. Kumar, A. Malhotra, C. Bal, Successful localization of residual culprit tumor in a case of tumor-induced osteomalacia using 68Ga-DOTANOC PET/CT. Clin Nucl Med. 38(8), 639–40 (2013). https://doi.org/10.1097/RLU.0b013e318279eb13
doi: 10.1097/RLU.0b013e318279eb13
pubmed: 23531775
K.B. Peters, R. McLendon, M.A. Morse, J.J. Vredenburgh, Treatment of recurrent intracranial hemangiopericytoma with SRC-related tyrosine kinase targeted therapy: A case report. Case Rep Oncol. 3(1), 93–7 (2010). https://doi.org/10.1159/000307468
doi: 10.1159/000307468
pubmed: 20740166
pmcid: 2918851
G.P. Clunie, P.E. Fox, T.C. Stamp, Four cases of acquired hypophosphataemic (’oncogenic’) osteomalacia. Probl. diagnosis, Treat long-term Manag Rheumatol (Oxf.) 39(12), 1415–21 (2000). https://doi.org/10.1093/rheumatology/39.12.1415
doi: 10.1093/rheumatology/39.12.1415
D.A. Mathis, E.J. Stehel, J.E. Beshay, B.E. Mickey, A.L. Folpe, J. Raisanen, Intracranial phosphaturic mesenchymal tumors: Report of 2 cases. J Neurosurg. 118(4), 903–7 (2013). https://doi.org/10.3171/2012.12.JNS12598
doi: 10.3171/2012.12.JNS12598
pubmed: 23350780
G. Nomura, Y. Koshino, H. Morimoto, H. Kida, S. Nomura, K. Tamai, Vitamin D resistant hypophosphatemic osteomalacia associated with osteosarcoma of the mandible: report of a case. Jpn J Med. 21(1), 35–9 (1982). https://doi.org/10.2169/internalmedicine1962.21.35
doi: 10.2169/internalmedicine1962.21.35
pubmed: 6279944
W. Xian-Ling, B. Jian-Ming, Z. Wen-Wen, L. Zhao-Hui, D. Jing-Tao, L. Ju-Ming et al. Osteomalacia caused by tumors in facies cranii mimicking rheumatoid arthritis. Rheumatol Int. 32(8), 2573–6 (2012). https://doi.org/10.1007/s00296-011-2018-4
doi: 10.1007/s00296-011-2018-4
pubmed: 21789616
G. Guglielmi, M. Bisceglia, A. Scillitani, A.L. Folpe, Oncogenic osteomalacia due to phosphaturic mesenchymal tumor of the craniofacial sinuses. Clin Cases Miner Bone Metab. 8(2), 45–9 (2011)
pubmed: 22461817
pmcid: 3279070
C. Bergwitz, M.T. Collins, A.E. R.S. Kamath, Rosenberg. Case records of the Massachusetts General Hospital. Case 33-2011. A 56-year-old man with hypophosphatemia. N Engl J Med. 365(17), 1625–35 (2011). https://doi.org/10.1056/NEJMcpc1104567
doi: 10.1056/NEJMcpc1104567
pubmed: 22029985
pmcid: 4907641
H. Wu, M.M. Bui, L. Zhou, D. Li, H. Zhang, D. Zhong, Phosphaturic mesenchymal tumor with an admixture of epithelial and mesenchymal elements in the jaws: clinicopathological and immunohistochemical analysis of 22 cases with literature review. Mod Pathol. 32(2), 189–204 (2019). https://doi.org/10.1038/s41379-018-0100-0
doi: 10.1038/s41379-018-0100-0
pubmed: 30206408
M.B. Zimering, F.A. Caldarella, K.E. White, M.J. Econs, Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes. Endocr Pract. 11(2), 108–14 (2005). https://doi.org/10.4158/EP.11.2.108
doi: 10.4158/EP.11.2.108
pubmed: 15901526
A. Nair, S. Chakraborty, P. Dharmshaktu, N. Tandon, Y. Gupta, R. Khadgawat et al. Peptide receptor radionuclide and octreotide: A novel approach for metastatic tumor-induced osteomalacia. J Endocr Soc. 1(6), 726–30 (2017). https://doi.org/10.1210/js.2016-1088
doi: 10.1210/js.2016-1088
pubmed: 29264524
pmcid: 5686685
X. Li, Y. Jiang, L. Huo, H. Wu, Y. Liu, J. Jin et al. Nonremission and recurrent tumor-induced osteomalacia: A retrospective study. J Bone Miner Res. 35(3), 469–77 (2019). https://doi.org/10.1002/jbmr.3903
doi: 10.1002/jbmr.3903
pubmed: 31643101
S. Yasuda, S. Wada, S. Kono, T. Miyajima, H. Oda, S. Katayama et al. Tumor-induced osteomalacia: benign tumor recurrence after two surgical resections at two different medical institutions. Endocr Pract. 19(4), e97–e101 (2013). https://doi.org/10.4158/EP13042.CR
doi: 10.4158/EP13042.CR
pubmed: 23512396
S. Basu, P. Fargose, 177Lu-DOTATATE PRRT in recurrent skull-base phosphaturic mesenchymal tumor causing osteomalacia: A potential application of PRRT beyond neuroendocrine tumors. J Nucl Med Technol. 44(4), 248–50 (2016). https://doi.org/10.2967/jnmt.116.177873
doi: 10.2967/jnmt.116.177873
pubmed: 27634982
G.G. Lee, H.-J. Dhong, Y.-S. Park, Y.H. Ko, Sinonasal glomangiopericytoma causing oncogenic osteomalacia. Clin Exp Otorhinolaryngol. 7(2), 145–8 (2014). https://doi.org/10.3342/ceo.2014.7.2.145
doi: 10.3342/ceo.2014.7.2.145
pubmed: 24917914
pmcid: 4050089
N. Weidner, R.S. Bar, D. Weiss, M.P. Strottmann, Neoplastic pathology of oncogenic osteomalacia/rickets. Cancer 55, 1691–705 (1985). 10.1002/1097-0142(19850415)55:8<1691::aid-cncr2820550814>3.0.co;2-s
doi: 10.1002/1097-0142(19850415)55:8<1691::AID-CNCR2820550814>3.0.CO;2-S
C. Fuentealba, D. Pinto, F. Ballesteros, D. Pacheco, O. Boettiger, N. Soto et al. Oncogenic hypophosphatemic osteomalacia associated with a nasal hemangiopericytoma. J Clin Rheumatol. 9(6), 373–9 (2003). https://doi.org/10.1097/01.rhu.0000101906.15276.ed
doi: 10.1097/01.rhu.0000101906.15276.ed
pubmed: 17043447
V.L. Woo, R. Landesberg, E.A. Imel, S.R. Singer, A.L. Folpe, M.J. Econs et al. Phosphaturic mesenchymal tumor, mixed connective tissue variant, of the mandible: report of a case and review of the literature. Oral Surg. Oral Med, Oral Pathol, Oral Radiol Endodontology 108(6), 925–32 (2009). https://doi.org/10.1016/j.tripleo.2009.07.005
doi: 10.1016/j.tripleo.2009.07.005
H.-C. Schober, C. Kneitz, F. Fieber, K. Hesse, H. Schroeder. Selective blood sampling for FGF-23 in tumor-induced osteomalacia. Endocrinol. Diabetes Metab. Case Rep. 2017 17-0006 (2017) https://doi.org/10.1530/EDM-17-0006
T. Hana, S. Tanaka, H. Nakatomi, M. Shojima, S. Fukumoto, M. Ikemura et al. Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23. Endocr J. 64(10), 1033–9 (2017). https://doi.org/10.1507/endocrj.EJ17-0177
doi: 10.1507/endocrj.EJ17-0177
pubmed: 28768937
J. Li, Y. Huang, F. Yang, Q. Zhang, D. Chen, Q. Wang, Sinonasal hemangiopericytoma caused hypophosphatemic osteomalacia: A case report. Med. (Baltim.) 97(52), e13849 (2018). https://doi.org/10.1097/MD.0000000000013849
doi: 10.1097/MD.0000000000013849
R. Tang, S. Mao, H. Lin, H.-B. Ye, D.-W. Li, Z.-N. Chen et al. Surgical treatment and outcomes for sinonasal and skull base phosphaturic mesenchymal tumors. Otolaryngol Head Neck Surg. 162(5), 674–82 (2020). https://doi.org/10.1177/0194599820904055
doi: 10.1177/0194599820904055
pubmed: 32122245
S. Liu, X. Zhou, A. Song, Z. Huo, Y. Wang, Y. Liu, Surgical treatment of recurrent spinal phosphaturic mesenchymal tumor-induced osteomalacia: A case report. Med. (Baltim.) 99(4), e18603 (2020). https://doi.org/10.1097/MD.0000000000018603
doi: 10.1097/MD.0000000000018603
M.I. Bhalla, K.M. Wirtz, E.S. Fair, D.J. Bucklan, 68Ga-DOTATATE positron emission tomography/computed tomography to detect the recurrence of phosphaturic mesenhcymal tumor-induced osteomalacia. World J Nucl Med. 19(1), 78–81 (2020). https://doi.org/10.4103/wjnm.WJNM_92_18
doi: 10.4103/wjnm.WJNM_92_18
pubmed: 32190030
Y. Li, Y. Li, M. Hui, Y. Liu, X. Liu, J. Jin et al. Comparison of surgical treatments of tumor-induced osteomalacia in different locations in the lower limbs: A retrospective study. Med. (Baltim.) 98(11), e14846 (2019). https://doi.org/10.1097/MD.0000000000014846
doi: 10.1097/MD.0000000000014846
A. Agaimy, M. Michal, S. Chiosea, F. Petersson, L. Hadravsky, G. Kristiansen et al. Phosphaturic mesenchymal tumors: Clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic spectrum. Am J Surg Pathol. 41(10), 1371–80 (2017). https://doi.org/10.1097/PAS.0000000000000890
doi: 10.1097/PAS.0000000000000890
pubmed: 28614212
S. Qiu, L.-L. Cao, Y. Qiu, P. Yan, Z.-X. Li, J. Du et al. Malignant phosphaturic mesenchymal tumor with pulmonary metastasis: A case report. Med. (Baltim.) 96(17), e6750 (2017). https://doi.org/10.1097/MD.0000000000006750
doi: 10.1097/MD.0000000000006750
H. Qari, A. Hamao-Sakamoto, C. Fuselier, Y.-S.L. Cheng, H. Kessler, J. Wright, Phosphaturic mesenchymal tumor: 2 new oral cases and review of 53 cases in the head and neck. Head Neck Pathol. 10(2), 192–200 (2016). https://doi.org/10.1007/s12105-015-0668-3
doi: 10.1007/s12105-015-0668-3
pubmed: 26577211
M.P. Yavropoulou, N. Gerothanasi, A. Frydas, E. Triantafyllou, C. Poulios, P. Hytiroglou et al. Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors. Endocrinol Diabetes Metab Case Rep. 2015, 150025 (2015). https://doi.org/10.1530/EDM-15-0025
doi: 10.1530/EDM-15-0025
pubmed: 26155363
pmcid: 4489167
S.C. Chua, S.R. O’Connor, W.L. Wong, R.H. Ganatra, Case report: Solitary plasmacytoma of bone with oncogenic osteomalacia: Recurrence of tumour confirmed by PET/CT. A case report with a review of the radiological literature. Br J Radio. 81(964), e110–e14 (2008). https://doi.org/10.1259/bjr/58168443
doi: 10.1259/bjr/58168443
N. Uramoto, M. Furukawa, T. Yoshizaki, Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx 36(1), 104–5 (2009). https://doi.org/10.1016/j.anl.2008.01.003
doi: 10.1016/j.anl.2008.01.003
pubmed: 18329207
K. Yoshioka, R. Nagata, M. Ueda, T. Yamaguchi, Y. Konishi, M. Hosoi et al. Phosphaturic mesenchymal tumor with symptoms related to osteomalacia that appeared one year after tumorectomy. Intern Med. 45(20), 1157–60 (2006). https://doi.org/10.2169/internalmedicine.45.1797
doi: 10.2169/internalmedicine.45.1797
pubmed: 17106161
A. Ogose, T. Hotta, I. Emura, H. Hatano, Y. Inoue, H. Umezu et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skelet Radiol. 30(2), 99–103 (2001). https://doi.org/10.1007/s002560000306
doi: 10.1007/s002560000306
K. David, T. Revesz, G. Kratimenos, T. Krausz, H.A. Crockard, Oncogenic osteomalacia associated with a meningeal phosphaturic mesenchymal tumor. Case Report. J Neurosurg. 84(2), 288–92 (1996). https://doi.org/10.3171/jns.1996.84.2.0288
doi: 10.3171/jns.1996.84.2.0288
pubmed: 8592237
J. Ding, L. Wang, S. Zhang, F. Li, L. Huo, Recurrent/Residual intracranial phosphaturic mesenchymal tumor revealed on 68Ga-DOTATATE PET/CT. Clin Nucl Med. 43(9), 674–5 (2018). https://doi.org/10.1097/RLU.0000000000002205
doi: 10.1097/RLU.0000000000002205
pubmed: 30015664
F. Allevi, D. Rabbiosi, M. Mandalà, G. Colletti, Mesenchymal phosphaturic tumour: early detection of recurrence. BMJ Case Rep. 2014, bcr2013202827 (20114) https://doi.org/10.1136/bcr-2013-202827
H.A. Fatani, M. Sunbuli, S.Y. Lai, D. Bell, Phosphaturic mesenchymal tumor: A report of 6 patients treated at a single institution and comparison with reported series. Ann Diagn Pathol. 17(4), 319–21 (2013). https://doi.org/10.1016/j.anndiagpath.2012.06.005
doi: 10.1016/j.anndiagpath.2012.06.005
pubmed: 22981782
M. Higley, B. Beckett, S. Schmahmann, E. Dacey, E. Foss, Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia. Skelet Radiol. 44, 1825–31 (2015). https://doi.org/10.1007/s00256-015-2246-x
doi: 10.1007/s00256-015-2246-x
R.G. Firth, C.S. Grant, B.L. Riggs, Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia. Report of two cases. Am J Med. 78(4), 669–73 (1985). https://doi.org/10.1016/0002-9343(85)90411-5
doi: 10.1016/0002-9343(85)90411-5
pubmed: 2984933
J.N. Harvey, C. Gray, P.E. Belchetz, Oncogenous osteomalacia and malignancy. Clin Endocrinol. (Oxf.) 37(4), 379–82 (1992). https://doi.org/10.1111/j.1365-2265.1992.tb02342.x
doi: 10.1111/j.1365-2265.1992.tb02342.x
A.L. Day, O.M. Gutiérrez, B.L. Guthrie, K.G. Saag, Burosumab in tumor-induced osteomalacia: A case report. Jt. Bone Spine 87(1), 81–3 (2020). https://doi.org/10.1016/j.jbspin.2019.07.012
doi: 10.1016/j.jbspin.2019.07.012
D. Rendina, G. De Filippo, L. Tauchmanovà, L. Insabato, R. Muscariello, F. Gianfrancesco et al. Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: A longitudinal study of five cases. Calcif Tissue Int. 85(4), 293–300 (2009). https://doi.org/10.1007/s00223-009-9275-1
doi: 10.1007/s00223-009-9275-1
pubmed: 19763378
E. Fernández-Cooke, J. Cruz-Rojo, C. Gallego, A.I. Romance, R. Mosqueda-Peña, Y. Almaden et al. Tumor-induced rickets in a child with a central giant cell granuloma: A case report. Pediatrics 2015 135(6), e1518–e23 (2015). https://doi.org/10.1542/peds.2014-2218
doi: 10.1542/peds.2014-2218
J.Y. Lee, H.S. Park, S. Han, J.K. Lim, N. Hong, S.I. Park et al. Localization of oncogenic osteomalacia by systemic venous sampling of fibroblast growth factor 23. Yonsei Med J. 58, 981–7 (2017). https://doi.org/10.3349/ymj.2017.58.5.981
doi: 10.3349/ymj.2017.58.5.981
pubmed: 28792142
pmcid: 5552653